Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK‐906), a Novel Selective D2/D3 Receptor Antagonist: A Phase 1 Randomized, Placebo‐Controlled Single‐ and Multiple‐Dose Escalation Study in Healthy Participants
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.906
Abstract: Gastroparesis is a chronic neuromuscular disorder of the upper gastrointestinal tract in which episodic exacerbation can lead to frequent hospitalizations and severe disability. Dopamine D2/D3 receptor antagonists have been used to treat patients with gastroparesis… read more here.
Keywords: receptor antagonist; trazpiroben tak; healthy participants; safety ... See more keywords
Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D2/D3 Selective Receptor Antagonist for the Management of Gastroparesis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Experimental Pharmacology"
DOI: 10.2147/jep.s332715
Abstract: Background Gastroparesis is characterized by delayed gastric emptying in the absence of mechanical obstruction. Owing to the potential for serious side effects, current treatments have restrictions on their use and there is a need for… read more here.
Keywords: system; safety; gastroparesis; day ... See more keywords